Tofacitinib vs Adalimumab Findings Require Caution in RA - Takeaways - MDSpire
From the Journals

Tofacitinib vs Adalimumab Findings Require Caution in RA

Meta-analysis favored tofacitinib for some rheumatoid arthritis outcomes, but high heterogeneity, dose-dependent effects, and JAK inhibitor safety concerns complicate interpretation.

  • By

  • Andrea Surnit

  • May 8, 2026

  • 4 min

Share

  • 1

    Tofacitinib shows greater improvement in ACR20 rates than adalimumab.

  • 2

    The review included 9 studies with 24,643 patients.

  • 3

    Concerns around long-term safety of JAK inhibitors are present.

  • 4

    Guidelines recommend caution for at-risk patients.

  • 5

    ACR20 responses demonstrated substantial heterogeneity.

  • 6

    Higher doses of tofacitinib led to improved outcomes.

  • 7

    Larger studies are needed to confirm findings.

Original Source(s)

Tofacitinib vs Adalimumab Findings Require Caution in RA

  • by Andrea Surnit

  • May 8, 2026

Related Content

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.

Deep Remission Tied to RA Control

At 5 years, 63% of patients in the CliDR group maintained sustained remission compared with 38% in the non-CliDR group.